News
DVAX
11.17
-2.19%
-0.25
Dynavax Technologies Enters Oversold Territory (DVAX)
NASDAQ · 3h ago
Weekly Report: what happened at DVAX last week (0415-0419)?
Weekly Report · 3d ago
After Hours Most Active for Apr 19, 2024 : MO, AAPL, INTC, DVAX, QQQ, CSCO, MSFT, NI, KO, NEM, UBER, TAL
NASDAQ · 6d ago
While shareholders of Dynavax Technologies (NASDAQ:DVAX) are in the black over 5 years, those who bought a week ago aren't so fortunate
Dynavax Technologies Corporation (NASDAQ:DVAX) saw its share price drop 18% in the last quarter. The stock is up 77% over the last five years, but is below the market return of 83%. In the last 5 years, the company's revenue has grown at 50% per year. The company didn't make a profit in last year, but its revenue growth has been strong. Dynavax technologies shareholders gained a total return of 4.2% last year.
Simply Wall St · 04/17 12:51
Weekly Report: what happened at DVAX last week (0408-0412)?
Weekly Report · 04/15 09:26
Weekly Report: what happened at DVAX last week (0401-0405)?
Weekly Report · 04/08 09:28
*Dynavax Technologies Corp: Appoints Ryan Spencer to Serve as Interim Chief Financial Officer While Kelly MacDonald Is on Maternity Leave
Dow Jones · 04/01 20:42
Dynavax Appoints Interim CFO During MacDonald’s Leave
TipRanks · 04/01 20:27
DYNAVAX TECHNOLOGIES CORP - ON MARCH 29 APPOINTED RYAN SPENCER TO SERVE IN A TEMPORARY CAPACITY AS INTERIM CHIEF FINANCIAL OFFICER
Reuters · 04/01 20:07
DYNAVAX TECHNOLOGIES CORP - KELLY MACDONALD IS ON MATERNITY LEAVE, TO RETURN IN EARLY AUGUST 2024 TO RESUME ROLE AS CHIEF FINANCIAL OFFICER
Reuters · 04/01 20:07
Weekly Report: what happened at DVAX last week (0325-0329)?
Weekly Report · 04/01 09:27
Weekly Report: what happened at DVAX last week (0318-0322)?
Weekly Report · 03/25 09:28
Dynavax Technologies: Still A Believer
Dynavax Technologies Corporation's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with potential sales reaching $400 million by FY27. Shares of vaccine maker Dynavax continue to trade at the lower end of their range. With positive prospects and a strong balance sheet, the company presents a solid long-term investment opportunity.
Seeking Alpha · 03/24 11:39
Dynavax: Holding Firm Despite Its Missing Cash Cow
Pandemic era CpG 1018 revenues are gone and unlikely to rekindle. HEPLISAV-B revenues create a reliable growing stream of income for Dynavax. The company is fairly valued at $1.92 billion. Cpg 1018 adjuvant is no longer viable as an independent source of revenue.
Seeking Alpha · 03/23 12:20
Dynavax (NASDAQ:DVAX) Offers Potentially Robust Growth at a Rich Valuation
TipRanks · 03/19 14:09
Weekly Report: what happened at DVAX last week (0311-0315)?
Weekly Report · 03/18 09:28
Dynavax Secures New Sublease Agreement Amidst Zymergen’s Bankruptcy
TipRanks · 03/12 20:26
Weekly Report: what happened at DVAX last week (0304-0308)?
Weekly Report · 03/11 09:27
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Dynavax Technologies Corporation (NASDAQ:DVAX) has debt on its balance sheet. The company has US$222.7m of debt, but also has a net cash position of US$742.3m. In the last year it shrunk its revenue by 68% to US$232m. We don't think the company is too risky in the near term. The future profitability of the company will determine its future.
Simply Wall St · 03/06 17:14
Weekly Report: what happened at DVAX last week (0226-0301)?
Weekly Report · 03/04 09:28
More
Webull provides a variety of real-time DVAX stock news. You can receive the latest news about Dynavax Technolo through multiple platforms. This information may help you make smarter investment decisions.
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.